A

Amgen

Makes biotech medicines for serious illnesses

Pharmacovigilance Operations Senior Manager

Full-TimeUpdated on 10/21/2026
No salary listed
Expert
Bachelor's, Master's, PhD, Associate's
Hyderabad, Telangana, India
In Person
Biology & BiotechRegulatory & Quality (Life Sciences)

About the job

Requirements
  • Deep expertise in pharmacovigilance safety systems, preferably ArisGlobal LifeSphere.
  • Strong experience with reporting and analytics platforms such as Cognos, Spotfire, or Tableau.
  • Working knowledge of Oracle databases, Oracle Developer, and programming languages such as Python or PL/SQL.
  • Solid understanding of data warehousing, analytics, and data mining techniques.
  • Proven experience with software development life cycle, system validation, and regulated development standards.
  • Strong understanding of global pharmacovigilance regulations and safety reporting requirements.
  • In-depth knowledge of clinical trial and pharmacovigilance operational processes.
  • Experience supporting regulatory inspections and internal audits in a leadership capacity.
  • Ability to interpret and apply aggregate safety data and analytics to regulatory and business decisions.
  • Proven ability to lead complex, cross-functional initiatives with minimal oversight.
  • Pharmaceutical industry and/or health authority experience is required.
  • Doctorate degree, or a master's degree and 3 years of directly related experience, or a bachelor's degree and 5 years of directly related experience, or an associate's degree and 10 years of directly related experience, or a high school diploma/GED and 12 years of directly related experience.
Responsibilities
  • Provide leadership and oversight for changes, enhancements, and configurations of the global safety system and associated data mart.
  • Own data integrity, consistency, and reliability standards for safety data used in analytics, regulatory submissions, and decision-making.
  • Oversee system configurations, including reporting rules, product and study setup, and integration points.
  • Direct and govern User Acceptance Testing activities to ensure validated, inspection-ready system changes.
  • Partner with Safety Technology and Managed Services to optimize system performance, support models, and service delivery.
  • Own the strategy, prioritization, and delivery of safety data outputs supporting periodic safety reporting, signal detection and safety surveillance, and regulatory inquiries, audits, and inspections.
  • Ensure timely, high-quality delivery of automated and scheduled safety reports.
  • Establish quality oversight, peer review standards, and continuous improvement for safety data outputs.
  • Lead the definition and implementation of reporting solutions, including user-defined reports, Query By Example, and optimized search strategies aligned with global standards.
  • Translate business requirements into scalable, compliant reporting solutions.
  • Provide strategic oversight for study start-up and integration activities, including EDC–Safety Database integrations, review and approval of Mapping Specifications Worksheets, and User Acceptance Testing planning, execution, and documentation.
  • Ensure integrations meet regulatory, validation, and data quality expectations.
  • Define and drive the roadmap for automation, artificial intelligence, and advanced analytics within pharmacovigilance operations.
  • Lead the evaluation, implementation, and validation of innovative technologies, including AI-assisted case processing, signal detection and analytics solutions, and reporting and workflow automation.
  • Partner cross-functionally to pilot and operationalize new capabilities while ensuring compliance, data integrity, and inspection readiness.
  • Monitor emerging technologies, industry trends, and regulatory expectations related to AI in pharmacovigilance.
  • Establish governance, documentation, and change management frameworks to ensure sustainable and compliant adoption of innovation.
  • Lead the development and delivery of training for safety systems, reporting tools, and associated processes.
  • Drive process standardization and continuous improvement through SOPs, work instructions, and user documentation.
  • Mentor and develop team members, strengthening technical depth and leadership capability.
  • Execute activities delegated by the Qualified Person for Pharmacovigilance as defined in the PV System Master File.
  • Maintain a continuous state of inspection readiness across systems, data, and processes.
  • Serve as a primary representative for health authority inspections and internal and external audits.
  • Own audit responses and remediation activities within scope of responsibility.
Desired Qualifications
  • Prior experience supporting pharmacovigilance systems, safety data analytics, or regulatory reporting is strongly preferred.
  • Case management experience is strongly preferred.

About the company

Amgen develops and makes biologic medicines, which are drugs built from proteins and antibodies grown in living cells, for serious conditions such as heart disease, cancer, and bone loss. Its anemia drug Epogen, approved in 1989, became one of the biotechnology industry's first blockbuster medicines. Amgen grows these drugs in large tanks called bioreactors, and its products include the cholesterol drug Repatha, the bone-building drug Evenity, and the severe asthma drug Tezspire. It earns money by selling these medicines, mostly through large drug wholesalers that supply hospitals and pharmacies. Amgen was founded in 1980 and is based in Thousand Oaks, California.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Growth is broad-based: 22 products grew at least 10%, lifting June 2026 quarter revenue 10% to $10.1 billion.
  • Stock grants gained value: Amgen shares rose 27% from January to October 9, 2026, versus 10% for rival Eli Lilly.
  • Many U.S. roles are remote: 145 of Amgen's 615 U.S. job openings in October 2026 were fully remote.

What critics are saying

  • Its 2025 best seller is shrinking: cheaper copies cut bone drug Prolia's sales 32% in the June 2026 quarter.
  • MariTide, Amgen's obesity bet, faces a giant: Lilly's Mounjaro and Zepbound outsold all of Amgen in the June 2026 quarter.
  • Most tech openings are in India: 156 of Amgen's 210 information systems jobs in October 2026 were in Hyderabad.

What makes Amgen unique

  • It copies rivals' blockbusters too: Pavblu, its version of Regeneron's eye drug Eylea, sold $700 million in 2025.
  • Amgen hunts drug targets in a nation's DNA: its Icelandic unit deCODE has genetic data on two-thirds of Iceland's adults.
  • Amgen opened a U.S. cancer-drug class: Blincyto, approved in 2014, was the first to tether immune cells to cancer.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Professional Development Budget
  • Conference Attendance Budget

Company News

Yahoo Finance
Oct 20th, 2026
Johnson & Johnson and Amgen beat the market in 2026, but can the dividend stocks keep going?

Johnson & Johnson and Amgen, two dividend stocks that have beaten the broader market this year, could suit investors bracing for a possible crash. J&J's latest quarter beat expectations, and it slightly raised its 2026 guidance. But its medtech unit is struggling, as demand for the Impella heart pump has fallen amid safety questions and a US Class 1 recall. Long-term, it has new drugs, a robotic surgery system approved in the US, and a proposed $5.5 billion talc settlement. It is a Dividend King with 64 straight years of payout increases. Amgen's second-quarter revenue rose 10% to $10.1 billion, despite pressure on Tavneos and falling denosumab sales. It has raised payouts 152% over a decade and offers a 2.3% forward yield, against 1.1% for the S&P 500.

Yahoo Finance
Oct 17th, 2026
Amgen raises 2026 revenue forecast to $38.8B as shares gain 15.2%

Amgen raised its fiscal 2026 revenue forecast on August 4 to $38.8 billion at the midpoint, up 2.6% from $37.8 billion. Adjusted earnings per share guidance rose to $22.90 from $22.40. Six key growth drugs grew 26% from a year earlier and made up nearly 70% of product sales in the June quarter. Repatha sales rose 37% to $953 million, offsetting a 33% drop in Prolia and XGEVA sales as biosimilar copies launched. Total revenue rose 10%. The stock has gained 15.2% since the release, against 1.9% for the S&P 500. It closed at $434.03 on October 15, above both its 50-day and 200-day averages. Reaching the midpoint requires $20.1 billion in the second half. Amgen's next report is expected around November 3.

Yahoo Finance
Oct 8th, 2026
Amgen invests $2.6B in manufacturing for MariTide obesity drug ahead of Phase III results

Amgen is testing MariTide, an experimental obesity drug designed to be dosed monthly or less frequently. The therapy has advanced into late-stage Phase III trials, with nine studies currently running and three more planned. Executives reported strong enrolment during the company's second-quarter 2026 earnings call on 4 August 2026. Amgen expects capital spending of about $2.6 billion in 2026, partly to scale manufacturing capacity for MariTide's eventual launch. The company is investing across its US manufacturing sites in North Carolina, Ohio, and Puerto Rico. Amgen stock has returned 44% over the past twelve months, outpacing the S&P 500's 17.1% gain. The company reported $38.1 billion in revenue over the last twelve months, up from $34.9 billion a year earlier.

Yahoo Finance
Sep 29th, 2026
Amgen lifts dividend 6%, but eroding Prolia and Enbrel sales shift focus to MariTide Phase 3

Amgen raised its quarterly dividend 6% to $2.52 per share, marking its 14th consecutive annual increase since starting payouts in 2011. The biotech now pays $10.08 annually, yielding 2.36% at current share prices of $418.13. The dividend appears well covered. Amgen generated $8.1 billion in free cash flow in 2025 against $5.1 billion in dividend payments. Second quarter 2026 free cash flow reached $3.5 billion whilst dividends consumed $1.4 billion. However, biosimilar competition is eroding legacy revenue. Prolia and XGEVA sales dropped 33% whilst Enbrel fell 37%. The company carries $57 billion in debt. Future dividend growth may hinge on Phase 3 results for MariTide, Amgen's obesity candidate. The company follows a steady raise pattern similar to Johnson & Johnson, contrasting with Pfizer's post-COVID payout struggles.

Yahoo Finance
Sep 26th, 2026
Vertex and Amgen deliver promising pipeline updates as both outperform market

Vertex Pharmaceuticals reported strong second-quarter results, with revenue rising 12% year-over-year to $3.33 billion and earnings per share climbing 8% to $4.31. The company posted positive Phase 2b results for inaxaplin, an experimental treatment for APOL1-mediated kidney disease, showing it reduced proteinuria in patients with modest protein levels and those with type 2 diabetes. Vertex expects approval for povetacicept, a treatment for IgA nephropathy, by November. The company continues diversifying beyond its core cystic fibrosis franchise, which provides predictable revenue as patients require lifelong treatment. Meanwhile, Amgen has also outperformed the broader market this year, though specific recent developments were not detailed in the source material.